Purpose We sought to investigate the utility of anti-PLA2R antibody as a non-invasive
screening method for the diagnosis of primary MN in patients with nephrotic syndrome (NS) …

Background Since the emergence of the anti-PLA2R antibody (PLA2R-Ab) test, nephrology
practice has not changed dramatically, with most nephrologists still relying on a kidney …

Rationale & Objective Proteinuria and anti–phospholipase A 2 receptor 1 (anti-PLA 2 R1)
antibody titers are associated with primary membranous nephropathy (MN) outcomes. We …

Introduction: Therapy in patients with primary membranous nephropathy is debated. The
discovery of anti-PLA2R antibodies provides opportunities for new treatment strategies …

EDITORIALS www. jasn. org with primary membranous nephropathy (MN), 1 our
understanding of the role of anti-PLA2R in clinical disease has evolved rapidly. The initial …

Background The 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines
recommend following anti-phospholipase A2 receptor (PLA2R) antibody levels as a marker …

Since urine samples more directly reflect kidney alterations and damage than blood
samples, we investigated whether urine anti-PLA 2 R antibody (uPLA 2 R-Ab) could be …

Background The currently recommended dose of rituximab for primary membranous
nephropathy is as high as that for lymphoma. However, the clinical manifestations of …

The phospholipase A2 receptor (PLA2R1) is the major autoantigen in idiopathic
membranous nephropathy. However, the value of anti-PLA2R1 antibody titers in predicting …

Results Antibodies were detected in 12 patients (54.54%): diagnosed (n= 5) and monitor (n=
7). All of patients with exacerbated disease process in monitored group had positive test …